

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## **APLNR RABBIT PAB**

货号: S216344

产品全名: APLNR 兔多抗

基因符号 APJ; APJR; HG11; AGTRL1

UNIPROT ID: P35414 (Gene Accession - BC032688)

背景: This gene encodes a member of the G protein-coupled receptor gene family. The encoded protein is related to the angiotensin receptor, but is actually an apelin receptor that inhibits adenylate cyclase activity and plays a counter-regulatory role against the pressure action of angiotensin II by exerting hypertensive effect. It functions in the cardiovascular and central nervous systems, in glucose metabolism, in embryonic and tumor angiogenesis and as a human immunodeficiency virus (HIV-1) coreceptor. Two transcript variants resulting from alternative splicing have been identified.

抗原: Fusion protein of human APLNR

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-200; ELISA: 1000-5000


种属反应性: Rabbit 克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse, Rat


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction, Metabolism, Neuroscience, Cardiovascular


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 216344(APLNR Antibody) at a dilution of 1/40(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 216344(Anti-APLNR Antibody) at dilution 1/40.



The image on the left is immunohistochemistry of paraffinembedded Human colon cancer tissue using 216344(Anti-APLNR Antibody) at a dilution of 1/40.



In comparision with the IHC on the left, the same paraffin-embedded Human colon cancer tissue is first treated with fusion protein and then with D220247(Anti-APLNR Antibody) at dilution 1/40.



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010